PMID- 18489990
OWN - NLM
STAT- MEDLINE
DCOM- 20080819
LR  - 20220316
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 14
IP  - 6
DP  - 2008 Jun
TI  - Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de 
      novo acute myelogenous leukemia with a conditioning regimen of total body 
      irradiation and granulocyte colony-stimulating factor-combined high-dose 
      cytarabine.
PG  - 651-7
LID - 10.1016/j.bbmt.2008.03.006 [doi]
AB  - We retrospectively evaluated the efficacy and safety of total body irradiation 
      (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose 
      cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell 
      transplantation (HSCT) in patients with de novo acute myelogenous leukemia (AML). 
      The conditioning regimen consisted of 12 Gy of TBI followed by high-dose 
      cytarabine (3 g/m(2)) every 12 hours for 4 days in combination with the 
      continuous administration of G-CSF. Stem cell sources included bone marrow or 
      peripheral blood stem cells (PBSC) from human leukocyte antigen (HLA)-identical 
      siblings (n = 24), or bone marrow from HLA serologically matched unrelated donors 
      (n = 26). Fifty patients (median age, 38 years) were evaluated. At HSCT, 35 
      patients were in the first or second complete remission (CR1/2), and 15 patients 
      were not in remission (n = 14) or in the third CR (n = 1). Thirty-six of 50 
      patients are currently alive, with a median follow-up period of 5.6 years (range: 
      1.1-12.1 years). The 5-year estimated overall survival (OS) and disease-free 
      survival (DFS) rates were 85.5% (95% confidence interval [CI], 73.7%-97.3%) and 
      82.1% (95% CI, 69.0%-95.2%) in patients with AML in the first or second CR, 46.7% 
      (95% CI, 21.4%-72.0%), and 40.0% (95% CI, 15.3%-64.7%) in patients with AML in 
      other stages. The 2-year cumulative incidence of treatment-related mortality 
      (TRM) of all patients was 10.4% (95% CI, 1.8%-18.6%). The only factors affecting 
      the OS and DFS were disease status at transplant and cytogenetics by multivariate 
      analysis. These results suggest that G-CSF-combined high-dose cytarabine could be 
      a promising component of the conditioning regimen for allogeneic HSCT for AML, 
      providing a high DFS and low TRM.
FAU - Mori, Takehiko
AU  - Mori T
AD  - Division of Hematology, Department of Medicine, Keio University School of 
      Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
FAU - Aisa, Yoshinobu
AU  - Aisa Y
FAU - Watanabe, Reiko
AU  - Watanabe R
FAU - Yamazaki, Rie
AU  - Yamazaki R
FAU - Kato, Jun
AU  - Kato J
FAU - Shimizu, Takayuki
AU  - Shimizu T
FAU - Shigematsu, Naoyuki
AU  - Shigematsu N
FAU - Kubo, Atsushi
AU  - Kubo A
FAU - Yajima, Tomonaru
AU  - Yajima T
FAU - Hibi, Toshifumi
AU  - Hibi T
FAU - Ikeda, Yasuo
AU  - Ikeda Y
FAU - Okamoto, Shinichiro
AU  - Okamoto S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Recombinant Proteins)
RN  - 04079A1RDZ (Cytarabine)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 6WS4C399GB (Lenograstim)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Bone Marrow Transplantation/adverse effects/mortality
MH  - Cytarabine/administration & dosage
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Humans
MH  - Infusions, Intravenous
MH  - Kaplan-Meier Estimate
MH  - Lenograstim
MH  - Leukemia, Myeloid, Acute/mortality/*surgery
MH  - Leukemia, Myelomonocytic, Acute/mortality/surgery
MH  - Male
MH  - Middle Aged
MH  - *Peripheral Blood Stem Cell Transplantation/adverse effects/mortality
MH  - Recombinant Proteins/administration & dosage
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Transplantation Conditioning/adverse effects/*methods/mortality
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Whole-Body Irradiation
EDAT- 2008/05/21 09:00
MHDA- 2008/08/20 09:00
CRDT- 2008/05/21 09:00
PHST- 2008/01/14 00:00 [received]
PHST- 2008/03/18 00:00 [accepted]
PHST- 2008/05/21 09:00 [pubmed]
PHST- 2008/08/20 09:00 [medline]
PHST- 2008/05/21 09:00 [entrez]
AID - S1083-8791(08)00115-8 [pii]
AID - 10.1016/j.bbmt.2008.03.006 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2008 Jun;14(6):651-7. doi: 
      10.1016/j.bbmt.2008.03.006.